Why is SLS stock soaring over 220% on Tuesday?
Sellas Life Sciences (SLS) stock surged 220% after reporting positive late-stage trial results for its cancer vaccine, GPS, which reduced death risk by 41% and extended median survival to 24 months in AML patients. The company plans to discuss an accelerated FDA approval pathway. SLS reported a net loss of $10.1 million in Q2. Trading was halted due to volatility.
How this was made
The 30-second read
Why it matters
The trial results provide a clear catalyst that could accelerate FDA discussions and a 2027 BLA filing, potentially unlocking significant valuation uplift.
Market read
The unprecedented 220% intraday surge underscores the market's reaction to breakthrough data in a high‑unmet‑need cancer area.
What to watch
Future BLA filing timing, manufacturing scale‑up costs, and competition from other AML therapies could temper upside.
Background
Sellas Life Sciences (SLS) is a clinical‑stage biotech focused on leukemia immunotherapies. The company has no revenue and reported a net loss of $10.1 M for the quarter.
Ticker impact
Sellas Life Sciences reported positive Phase 3 trial results for its GPS vaccine, driving a 220% stock surge.
upward pressure as investors price in the survival benefit and potential FDA pathway.
The trial shows a 41% mortality reduction and a median OS gain of 9.3 months, a material clinical milestone for a biotech.
Market effects
Strengthens the AML‑focused biotech niche and may lift peer companies developing immunotherapies.
Positive for US biotech sector; limited broader market effect.
Highlights the potential of cancer vaccines, could attract global investor interest.
Counterpoint
The data are from a single trial; regulatory approval is not guaranteed and the stock may be overbought after a 220% jump.
Key entities
- CEOAngelos Stergiou
CEO of Sellas who commented on the trial milestone.

